Open-Label Trial on the Effects of Memantine in Adults With Obsessive-Compulsive Disorder After a Single Ketamine Infusion
Year: 2016
Type: article
Abstract: Article AbstractBecause this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.To the Editor: The only first-line pharmacologic treatments recommended for obsessive-compulsive disorder (OCD) are serotonin reuptake inhibitors (SRIs). We found that a single intravenous (IV) dose of ketamine, an N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, rapidly decreases symptoms in unmedicated patients with OCD, demonstrating that a drug affecting glutamate transmission can reduce OCD symptoms without an SRI. After study participation, patients often requested a drug with similar effects to ketamine that could be taken as an outpatient.
DOI: 10.4088/jcp.15l10318
Language: English
Subfield: Clinical Psychology
Field: Psychology
Domain: Social Sciences
Open Access status: green
OpenAlex ID: W2395135497
